Huawei's Diabetes Risk Study brings non-invasive screening to Watch GT 6 Pro
The PPG-based feature provides diabetes screening without finger-prick tests
Huawei has taken a giant leap towards wrist-based metabolic tracking, unveiling a non-invasive diabetes risk assessment tool for its Watch GT 6 Pro. This groundbreaking innovation was announced at the World Health Expo 2026 in Dubai, marking a significant milestone in the company's Diabetes Risk Study.
The study's unique approach eliminates the need for direct mmol/L readings, instead employing a risk-modeling technique. This feature is currently being rolled out to the smartwatch via an over-the-air update, utilizing the device's PPG sensors to detect vascular and heart rate patterns associated with insulin resistance and prediabetes.
To ensure the technology's credibility, Huawei has partnered with Dubai Health for a comprehensive validation study. The project involves 150 participants, divided equally between healthy, pre-diabetic, and diabetic volunteers, who are being monitored at Dubai Health facilities.
The study's focus is on evaluating the tool across diverse skin tones and physiological backgrounds, with results compared to clinical gold standards such as Fasting Blood Glucose, HbA1c, and Oral Glucose Tolerance Tests (OGTT). This meticulous oversight, including strict fasting guidelines and anonymized data collection, aims to produce a validation report that could set a new standard for wearable health credibility.
For users, the Diabetes Risk app requires a monitoring period of 3-14 days to gather sufficient data during rest and activity for building a physiological profile. It provides a 'Low', 'Medium', or 'High' risk assessment, serving as a screening tool rather than a diagnostic one. Those flagged in the higher categories are advised to seek professional medical evaluation.
While regional certification means the feature isn't available globally yet, particularly in the US or Europe, it represents a significant advancement in transforming smartwatches into passive monitors for chronic conditions.
